At our InnovationWell Community of Practice Autumn Meeting on Innovation in Life Science & Healthcare Research & Product Development (16-19 October 2006, Bryn Mawr, Philadelphia) we will be concentrating on themes of relevance to FDA’s Critical Path initiative integrated into our ongoing themes of innovation and knowledge management in life science and healthcare product development and safety. The themes of knowledge management in clinical and translational research, decision support for R&D, Metabolomics, Predictive Toxicology and Biomarkers & Systems Biology approaches will be covered in four days of InterAction Meeting program sessions. In addition to morning presentations and panel discussions, workshops will run each afternoon expanding on discussions of topics, methods and practices, with bbq, social activity and poster sessions running on campus during the evenings.
Michael Liebman (Windber Research Institute) will chair a program examining the application of Knowledge Management techniques to increase R&D Productivity along Critical Paths in clinical and translational research and will be joined by Delia Y. Wolf (Harvard Medical School), Peter Gates (Johnson & Johnson PR&D), Jonathan Sheldon (InforSense), Duane Shugars (Concentia Digital), Jian Wang (Biofortis), and Jeff Spitzner (Rescentris).
The Decision Support for Research & Development will examine the application of knowledge and risk management, systems biology, analytics, and new technologies in improving productivity and decision making in R&D, clinical research and development. Presenters include Peter Henstock (Pfizer), Craig Liddell (Realtime Science), David Mosenkis (Spotfire), Joel Hoffman (IntraSphere), and Dennis Underwood (Praxeon).
A Metabolomics in Discovery & Development Day is being chaired by George Harrigan (Monsanto) and co-sponsored by the Metabolomics Society and includes presentations and workshops from Rick Beger (NCTR, FDA), Alvin Berger (Metabolon), Don Robertson (Pfizer), Gregory Banik (Bio-RAD), Teresa Garret (Duke University), Susan Connor (Glaxo SmithKline), Laszlo Boros (SIDMAP), Bruce Kristal (Cornell University), Stanley Young (NISS) and Andrew Lane (JG Brown Cancer Center, U. Louisville).
The FDA has identified the development of new biomarkers as one of the key opportunities to increase efficiency, predictability, and productivity in drug development. A session on the application of Biomarkers in Drug Development will explore new advances and challenges in this area and will include a keynote from Keith Elliston, CEO (Genstruct), with Zentam Tsuchihashi (BMS) discussing Biomarker Roles in Tumor Immunotherapy, while Darius Dziuda (CCSU) will cover the topic of Multivariate Biomarkers.
The Pedictive Toxicology session brings together leading ADME & Tox experts and includes a Keynote from Tudor Oprea and seminars from Navita Mallalieu (Roche), Alex Tropsha (UNC), Curt Breneman (RPI), Karim Kassam (ACD/Labs), Michael Bolger (USC School of Pharmacy), Bob Clark (Tripos), and Gilles Klopman (Multicase).
The program also includes eCheminfo Drug Discovery sessions on Structure-based Drug Design, Screening, and Medicinal Chemistry, which are also available to all registrants to attend. (http://www.echeminfo.com/COMTY_conferences/)Program and schedule information can be viewed at
Please address any questions related to the conference, exhibition or workshop program to Dr. Barry Hardy, InnovationWell Community of Practice Manager, +41 61 851 0170, barry.hardy [at] douglasconnect.com. Registration enquiries should be directed to innovationwell [at] douglasconnect.com
InnovationWell meeting workshop conference management executive Bryn Mawr Philadelphia Critical Pathbiomarkers metabolomics toxicology personalised medicine KM Life Sciences Pharma Drug DiscoveryResearch and Development Drug Development Healthcare Innovation Knowledge Management events